-
Professor Chen Li: Public report! Celiniso in combination with chemotherapy has been shown to bring effective remission in patients with relapsed/refractory plasmablastic lymphoma
Time of Update: 2023-01-06
Poke "Read Original" to see moreBased on the mechanism of action of celinisol, its broad-spectrum anti-tumor effect and synergistic effect with a variety of chemotherapy drugs, Professor Chen Li's team applied celiniso combined with GDP chemotherapy to patients with PBL, and sorted out the specific cases and published them in the Journal of Clinical Hematology, which is also the first public report on the treatment of PBL by celiniso.
-
The 2022 CSCO Academic Annual Conference Harbin Branch &The 7th Anti-Leukemia and Lymphoma International Summit Forum was grandly held!
Time of Update: 2023-01-06
The conference set up a number of academic sessions such as academician forum, leukemia and lymphoma, lymphoma youth forum, leukemia youth forum, and drug regulatory policy (UCLI-CDE) session, and specially invited famous experts and scholars in the field of hematological oncology at home and abroad to discuss the cutting-edge progress and hot topics in the fields of leukemia, lymphoma and myeloma.
-
The 2022 CSCO Academic Annual Conference Harbin Branch &The 7th Anti-Leukemia and Lymphoma International Summit Forum was grandly held!
Time of Update: 2023-01-06
The conference set up a number of academic sessions such as academician forum, leukemia and lymphoma, lymphoma youth forum, leukemia youth forum, and drug regulatory policy (UCLI-CDE) session, and specially invited famous experts and scholars in the field of hematological oncology at home and abroad to discuss the cutting-edge progress and hot topics in the fields of leukemia, lymphoma and myeloma.
-
【ASH Express】Reproduce eye-catching data-a quick overview of the blockbuster study of the classic BTK inhibitor ibrutinib
Time of Update: 2023-01-06
The 2022 American Society of Hematology (ASH) Annual Meeting will be held in New Orleans from December 10 to 13 Eastern Time in the form of online + offline, the abstract will be announced at 22:00 Be
-
【ASH Express】Reproduce eye-catching data-a quick overview of the blockbuster study of the classic BTK inhibitor ibrutinib
Time of Update: 2023-01-06
The 2022 American Society of Hematology (ASH) Annual Meeting will be held in New Orleans from December 10 to 13 Eastern Time in the form of online + offline, the abstract will be announced at 22:00 Be
-
Research Express! Iberdomide in combination with dexamethasone in the treatment of advanced R/R MM is a new progress
Time of Update: 2023-01-06
Multiple myeloma (MM) is characterized by the persistence of minimal residual disease during combination therapy by patients, leading to multiple cycles of remission and recurrence. Each subsequent li
-
The innovative CD20 monoclonal antibody set sail in the wave of standardized treatment of indolent lymphoma
Time of Update: 2023-01-06
▎Professor Zhang Qingyuan:In the clinical treatment of FL, obinutuzumab has a wealth of evidence-based medical evidence, including the GALLIUM study is a global multicenter, randomized controlled phase III study comparing the efficacy of obinutuzumab in combination with chemotherapy (G-chemotherapy group) and rituximab plus chemotherapy regimen (R-chemotherapy group) in induction therapy in patients with treatment-naïve FL 。 Results showed that the G-chemotherapy regimen significantly improved PFS (3-year PFS rate 80.
-
【2022 ASH Field Frontier】Treatment status and stratified prognosis of multiple myeloma
Time of Update: 2023-01-06
Poster #4518The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma PatientsKey author: Hongying YouKey information: Clinically significant end-stage organ damage and high tumor burden in 1q21+ patients are independent high-risk cytogenetic factors for poor prognosis in patients with NDMM, where 4 or more copy numbers and major clone locations are significantly associated with prognosis.
-
【2022 ASH Field Frontier】Treatment status and stratified prognosis of multiple myeloma
Time of Update: 2023-01-06
Poster #4518The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma PatientsKey author: Hongying YouKey information: Clinically significant end-stage organ damage and high tumor burden in 1q21+ patients are independent high-risk cytogenetic factors for poor prognosis in patients with NDMM, where 4 or more copy numbers and major clone locations are significantly associated with prognosis.
-
Yi Shuo Blood New Time and Space Gathering Chinese and foreign forces, talking about multidisciplinary progress, MM International Exchange Conference was grandly held
Time of Update: 2023-01-06
The content is rich and rewarding, I hope that all colleagues, especially young doctors, will ponder this repeatedly and move forward firmly!At the end of the conference, Professor Chen Wenming, the chairman of the conference, concluded that the conference showed the considerable results of clinical trials, and then sublimated to real-world patient data statistics, and explained in detail the treatment strategies of MM and the development of high-quality real-world research through Sino-foreign exchanges and interdisciplinary sharing.
-
Another gene therapy coming? FDA updates regulatory progress for hemophilia therapy
Time of Update: 2023-01-05
▲If you have any business needs, please press and hold to scan the QR code above, or▎WuXi AppTec content team editorToday, BioMarin Pharmaceutical announced that it has been notified that the FDA no longer plans to hold an advisory committee meeting to discuss the Biologics License Application (BLA) for Roctavian (valoctocogene roxaparvovec).
-
Moving forward, leukemia and lymphoma special session 3 explores new progress in hematological tumors The Harbin branch of the 2022 CSCO Academic Annual Conference
Time of Update: 2023-01-05
Professor Qiu Lin and Professor Lai Yongrong presidedResults of a phase Ib/IIa clinical study of MIL62 injection combined with orelabrutinib tablets in the treatment of r/r B-NHLProfessor Shi Yuankai gave a wonderful reportProfessor Shi Yuankai from Cancer Hospital of Chinese Academy of Medical Sciences shared the results of a phase Ib/IIa clinical study evaluating the safety and efficacy of MIL62 injection combined with orelabrutinib tablets in the treatment of r/r B-NHL.
-
Professor Gong Tiejun: Therapeutic progress of targeted therapy in young patients with acute myeloid leukemia The 7th International Summit Forum on Anti-Leukemia and Lymphoma
Time of Update: 2023-01-05
Recently, a number of new drug marketing applications on the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration have attracted much attention, so what are the exploration of targeted therapy in young AML patients?Professor Gong TiejunResearch progress on targeted drugs, including chimeric antigen receptor T cell (CAR-T) therapy, bispecific antibody drugs and antibody drug conjugates, focuses on lymphoma, myeloma and acute lymphoblastic leukemia.
-
Micro-classroom No. 18 Professor Luo Jun: The latest exploration of MRD detection and application
Time of Update: 2023-01-05
Figure 3 Consistency between MS and NGS detectionThe 2022 EHA Conference also presented a study4 comparing the accuracy of NGF and functional imaging in MRD assessment and exploring the guiding significance of MRD in consolidation therapy.
-
【Lancet Haematol】Ponatinib and Belintoumab bring Ph+ ALL into deep remission, is there no need for transplantation?
Time of Update: 2023-01-05
Ph+ ALLNewly diagnosed Philadelphia chromosome-positive (Ph+) adult acute lymphoblastic leukemia (ALL) patients are treated with intensive chemotherapy plus TKI, followed by allogeneic hematopoietic s
-
Cancer Med: the immune checkpoint gene VSIR predicts prognosis in patients with acute myeloid leukemia and myelodysplastic syndromes
Time of Update: 2023-01-04
Figure 4: VSIR expression in single cells associated with leukemiaFigure 5: Prognostic value of VSIR in other blood cancer types.
Figure 4: VSIR expression in single cells associated with leukemiaFigure 5: Prognostic value of VSIR in other blood cancer types.
-
I can't understand the blood coagulation results, and the eight modes are easy to get!
Time of Update: 2023-01-04
Mode 6: PT, APTT and TT are significantly elevated, FBG is low, DD is normal or elevated This mode, the most common cause is liver disease (such as cirrhosis), resulting in insufficient synthesis of various coagulation factors in the liver.
-
Common causes of lymphocytosis or decrease [Note]
Time of Update: 2023-01-04
Pathological increase(1) infection:(2) Tumors:(3) Recovery period of acute infectious diseases(4) Transplant rejection:(5) Relative increase in lymphocyte ratio:3.
Reactive(1) infection:(2) Drug allergy(3)After blood transfusion, hemodialysis or cardiopulmonary bypass,(4)Others:
-
Fifth edition of the WHO classification MDS and AML (Interpretation Update)
Time of Update: 2023-01-04
1. The name WHO-HAEM5 renamed myelodysplastic syndroms (MDS) as myelodysplastic neoplasms (MDN), the factors of the name change, one of which emphasizes that MDS is a tumor nature, The second is consistent with the naming of myeloproliferative tumors (MPNs).
-
Everything you want to know about bevacizumab is here!
Time of Update: 2023-01-04
1. Applicable diseases Bevacizumab is a recombinant humanized monoclonal antibody that inhibits VEGF binding to its receptors by specifically targeting human vascular endothelial growth factor (VEGF), inhibits the formation of tumor blood vessels, reduces the supply of blood, oxygen and other nutrients to tumors, thereby inhibiting tumor cell growth.
